Stem cells

Stem cell researcher in line to become Australian of the Year 2017

Posted on Updated on

Alan is acknowledged as having laid the foundation for the next generation of researchers in his field. Photo David Kelly

ALAN Mackay-Sim’s fascination with the human body stretches back to his childhood in Sydney.

“I remember being about 12 and wandering down an uneven bush track and thinking, ‘How the hell can I walk along here and compensate for the ground, the uneven ground, and it’s all automatic?’” He says. “It was a feeling of wonder at how we work and I remember even then thinking I’d one day like to figure it out.”

Today the celebrated biomedical scientist and professor at Queensland’s Griffith University is a world authority on the human sense of smell and his groundbreaking work with stem cells has given hope to thousands of Australians with spinal cord injuries.

As director of the National Centre for Adult Stem Cell Research, Alan championed has the use of stem cells to understand brain disorders and diseases including schizophrenia, Parkinson’s disease and hereditary spastic paraplegia.

Though he is now retired, Prof Alan Mackay-Sim’s goal is to progress clinical trials in a drug that he and his team have found for a disease called hereditary spastic paraplegia.

He also led the world’s first clinical trial using stem cells to treat spinal cord injury.

In 2014 Alan’s research played a key role in the first ever successful restoration of mobility in a paraplegic person. “The patient was a man in Poland who had a stab wound to his spinal cord in the thoracic chest region,” says Alan.

“Since the treatment he’s standing, he’s walking on a walker and this year I’ve seen a video of him walking better and riding a tricycle around a gym. His feet are strapped in but he can deliver power to his legs to ride and to steer and … it’s bloody amazing!”

Ever the scientist, however, Alan cautions that much work lies ahead if progress is to be made in benefiting other people with spinal cord injuries. “While the patient in Poland is a very good achievement, it’s scientifically the conservative to say, ‘Well that’s one example. Give me some more examples,’” says Alan.

“It’s three years since he had the injury and the odds are that this is because he had these cells put in his spinal cord rather than some other effect but, you know, yes — you really need to repeat it to show that it’s pretty impressive.”

Mackay-Sim led the world’s first clinical trial using stem cells to treat spinal cord injury.

Although retired, Alan remains emeritus professor at Griffith University and lists repeating the success that was had in Poland as one of his major goals. “We have a team whose intentions are to move the clinical trials forward,” he says. “I’m chair of a scientific advisory board for that so that’s one goal — to see the next phase of clinical trials.

“My other goal is to progress our clinical trials in a drug that we’ve found for a disease called hereditary spastic paraplegia. We’ve got a drug that we’re going to take to clinics to phase one clinical trials, for safety trials. My goal would be to take that through to phase two, which is the efficacy trial, and to get that drug into the population.”

Today, Alan is acknowledged as having laid the foundation for the next generation of researchers in his field and says the future of medical science is immensely exciting.

“I started my university degree in 1970,” he says. “In that time our understanding of neuroscience has multiplied 1000 times over. And with the technologies that are available, and with our application of all sorts of chemistries; all sorts of computing techniques, all sorts of machinery and instruments, technologies like the genome, the stem-cell technologies — these are all huge developments.”

“It’s an exciting time to be around and if we can afford the science I can definitely say can there’s a rosy future for humanity ahead.”

CommBank have been proud partners of Australian of the Year Awards for over 37 years, celebrating and championing those who make our country a better place. The awards honour an extraordinary group of respected Australians, whose actions inspire conversation on issues of national importance.

Source: 1

Advertisements

Scientists just used stem cells from one monkey to heal the hearts of five others

Posted on Updated on

Scientists in Japan have used cardiac muscle cells derived from the stem cells of a macaque to mend the damaged hearts of five other monkeys.

The technique shows that using donor stem cells might one day be a viable way to regenerate the organs of human heart attack patients – an approach that could dramatically reduce the time and expense of developing individualised stem cell treatments.

While using stem cell therapy to treat conditions like heart problems isn’t new, the technique usually involves cultivating stem cells taken from the patient themselves – which can be very expensive.

Alternatively, stem cells can be harvested from human embryos, but that procedure is controversial, since the embryo is destroyed in the process.

If the new technique demonstrated by researchers at Shinshu University can be replicated in humans, we could avoid these difficulties in future stem cell therapies by enabling scientists to develop a resource of ready-made, donor-based treatments to help any number of patients.

“They strengthen the case that a bank of pre-prepared matched [cells] could be used to treat patients, without relying on the long process of reprogramming and differentiating the patient’s own cells,” cardiac researcher Sian Harding from Imperial College London in the UK, who wasn’t involved with the study, told Ian Sample at The Guardian.

In the study, the researchers generated induced pluripotent stem cells (reprogrammed cells) taken from the skin cells of a donor macaque. They then injected these cells into damaged areas in the hearts of five recipient macaques that had each experienced an induced heart attack.

Of course, one of the major risks of using donor cells is the possibility of rejection by the recipient – if you’re using individualised stem cells (cells taken from the patients themselves) there’s no chance of rejection of foreign cells via an immune response.

To address the risk of rejection, the researchers here selected animals that were as close to a genetic match as possible in terms of a shared immune system protein called major histocompatibility complex (MHC).

“In addition to daily treatments of the immunosuppressant drugs methylprednisolone and tacrolimus, we made sure the surface protein MHC, which is used by the immune system to recognise foreign cells, was carefully matched on the donor and recipients’ cells,” one of the researchers, Yuji Shiba, told Maarten Rikken at ResearchGate.

After monitoring the recipient macaques for 12 weeks, there was no sign of rejection, and the team observed that the transplanted cells had improved the damaged hearts’ ability to contract.

That said, there was one notable side effect. The recipient monkeys showed an increased incidence of irregular heartbeats – a condition known as arrhythmia – but the team says they’re confident that the condition didn’t pose any serious health risks to the animals before they were euthanised at the conclusion of the trial.

“Ventricular arrhythmia was induced by the transplantation, typically within the first four weeks,” Shiba told ResearchGate.

“However, this post-transplant arrhythmia seems to be transient and non-lethal. All five recipients of [the stem cells] survived without any abnormal behaviour for 12 weeks, even during the arrhythmia. So I think we can manage this side effect in clinic.”

While it’s an exciting result that demonstrates the potential for donor-based stem cell transplants in treating heart damage in the future, we can’t get too excited just yet.

The researchers acknowledge that their small study only involved five recipient animals, so larger trials with more animals are needed to replicate the results.

And while the treatment was successful in this case, the monkeys that received it were only observed for three months afterwards, meaning we don’t know the longer-term prospects for this experimental therapy.

But despite the limitations, it’s still a promising new lead for stem cell research – especially for heart attack patients and their families, who may not have many other alternatives.

“Currently, the only long-term option for these patients is heart transplantation,” cardiac researcher Sam Boateng from Reading University in the UK told The Guardian, “but there are not enough donors to meet the current demand.”

The findings are reported in Nature.

Source: 1